In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant's Guiding Spirit: An Interview with Beverly Lorell, MD

Executive Summary

Like all medical device companies, Guidant is facing a world of unprecedented changes, most notably the emergence of drug/device therapies that will require radically different skill sets and development strategies. To help it cope with the challenges and opportunities to come, Guidant reached into the academic cardiology community, appointing an internationally-recognized expert in interventional cardiology and heart failure, Beverly Lorell, to oversee the future of its device technology. Lorell will be no ivory-tower academic. She'll help Guidant understand the clinical issues while working through the related business issues, including the growing complexity of the clinical trials process and the proper influence that marketing and sales imperatives should play on product development.

You may also be interested in...



How To Fix A Guidant: Boston Scientific's Tobin Opens Playbook

Boston Scientific CEO Jim Tobin, in a series of addresses, defends his company's decision to spend $27.3 billion on Guidant Inc., warts and all. Defying criticism of the deal, Tobin lays out how Boston Scientific management corrected Guidant's problems--and why the new company will thrive.

X-Cell Medical: Putting Safety First

Most medical device start-ups seeking to tap into the enormous drug-eluting stent market have focused on novel stent or stent platform design, on the theory that drug efficacy is a given. But X-Cell Medical is betting that they've come up with a better drug. And they're making their case by stressing the importance of safety.

X-Cell Medical: Putting Safety First

Most medical device start-ups seeking to tap into the enormous drug-eluting stent market have focused on novel stent or stent platform design, on the theory that drug efficacy is a given. But X-Cell Medical is betting that they've come up with a better drug. And they're making their case by stressing the importance of safety.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS142217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel